Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

KALV

KalVista Pharmaceuticals Inc

Feb 13 • 04:00PM ET

14.91

-0.21 -1.39 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE RARE CORT QURE VKTX VSTM PVLA CYPH XERS XBIO

| Held by: VTI XBI IWM VXF IWO IBB LFSC VTWO SCHA FESM

Index	RUT	P/E	-	EPS (ttm)	-4.00	Insider Own	25.14%	Shs Outstand	50.54M	Perf Week	0.07%
Market Cap	753.65M	Forward P/E	16.38	EPS next Y	0.91	Insider Trans	-0.74%	Shs Float	37.84M	Perf Month	-2.17%
Enterprise Value	727.07M	PEG	-	EPS next Q	-	Inst Own	99.56%	Short Float	53.02%	Perf Quarter	11.77%
Income	-203.10M	P/S	527.02	EPS this Y	87.71%	Inst Trans	0.65%	Short Ratio	16.12	Perf Half Y	15.14%
Sales	1.43M	P/B	44.33	EPS next Y	300.74%	ROA	-97.71%	Short Interest	20.06M	Perf YTD	-7.68%
Book/sh	0.34	P/C	2.44	EPS next 5Y	-	ROE	-190.18%	52W High	19.00 -21.53%	Perf Year	56.45%
Cash/sh	6.12	P/FCF	-	EPS past 3/5Y	-3.17% -17.63%	ROIC	-68.88%	52W Low	8.99 65.82%	Perf 3Y	82.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-9.33%	Volatility	4.91% 5.79%	Perf 5Y	-64.98%
Dividend TTM	-	EV/Sales	508.44	EPS Y/Y TTM	-13.14%	Oper. Margin	-14220.90%	ATR (14)	0.90	Perf 10Y	98.32%
Dividend Ex-Date	-	Quick Ratio	7.21	Sales Y/Y TTM	-	Profit Margin	-14242.57%	RSI (14)	46.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.22	EPS Q/Q	-1.45%	SMA20	-2.70%	Beta	-0.34	Target Price	33.78
Payout	-	Debt/Eq	16.62	Sales Q/Q	-	SMA50	-4.72%	Rel Volume	0.40	Prev Close	15.12
Employees	270	LT Debt/Eq	16.34	Earnings	Dec 04	SMA200	9.70%	Avg Volume	1.24M	Price	14.91
IPO	Apr 09, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.50% -100.00%	Trades		Volume	499,248	Change	-1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Reiterated	Needham	Buy	$32 → $35
Jan-06-26	Reiterated	Needham	Buy	$28 → $32
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$19
Jan-07-25	Initiated	TD Cowen	Buy	$30
Dec-18-24	Initiated	BofA Securities	Buy	$22
Jun-15-20	Initiated	H.C. Wainwright	Buy	$30
Jul-29-19	Initiated	SVB Leerink	Outperform	$31
Mar-20-19	Initiated	Needham	Buy	$35
Oct-30-18	Initiated	Jefferies	Buy	$30
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy	$18

Show Previous Ratings

Feb-12-26 07:00AM	KalVista Pharmaceuticals to Present EKTERLY (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-03-26 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-02-26 09:55AM	Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade (Zacks)
09:48AM	TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results (Insider Monkey)
Jan-15-26 09:55AM	Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? (Zacks)
09:56AM	Loading…
Jan-09-26 09:56AM	KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug (Benzinga) +6.19%
05:43AM	Stock Market Today: Nasdaq 100, S&P 500 Futures Gain As Investors Await December Jobs Report- General Motors, Offerpad, Tilray In Focus (Benzinga)
Jan-08-26 04:05PM	KalVista Pharmaceuticals Provides Update on Strong EKTERLY Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results (Business Wire)
Dec-22-25 06:00AM	KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks) +11.87%
Dec-03-25 04:09PM	Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment (Investor's Business Daily) +8.43%
Nov-18-25 06:16AM	Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects (Insider Monkey)
Nov-11-25 04:02PM	KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... (GuruFocus.com) +5.33% +16.30%
Nov-10-25 05:45PM	KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:30PM	KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results (Business Wire)
08:01AM	Loading…
Nov-06-25 08:01AM	KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting (Business Wire)
Nov-05-25 07:00AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 (Business Wire)
Oct-30-25 07:00AM	KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting (Business Wire)
Oct-06-25 04:00PM	KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe (Business Wire) -7.51%
07:00AM	KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer (Business Wire)
Oct-03-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-02-25 07:00AM	KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors (Business Wire)
Sep-26-25 07:00AM	KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 20th German Allergy Congress (Business Wire)
Sep-24-25 10:52PM	KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 (Business Wire) -6.46%
04:01PM	KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes (Business Wire)
Sep-19-25 07:00AM	KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema (Business Wire) -5.12%
Sep-12-25 09:00AM	Morning Movers: Kroger rises following second quarter results (TipRanks) -5.40%
03:01AM	KalVista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Highlights: EKTERLY Launch Drives ... (GuruFocus.com)
Sep-11-25 08:05AM	KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results (Business Wire)
04:55AM	Adobe earnings on tap as stock badly lags the broader market (MarketWatch)
04:13AM	Stock Market Today: S&P 500 and Nasdaq hold record highs, Dow near peak, as AI excitement lingers and investors hope CPI inflation data will confirm Fed rate cut trajectory. (MarketWatch)
Sep-04-25 07:05AM	KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025 (Business Wire) +7.34%
07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-25 02:00PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
07:00AM	KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-11-25 04:05PM	Metagenomi Appoints Laurence Reid, PhD to its Board of Directors (GlobeNewswire)
07:00AM	KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union (Business Wire)
Aug-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-25 01:31AM	KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency (Insider Monkey)
Jul-25-25 08:00AM	KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks (Business Wire) -6.54%
Jul-15-25 04:05PM	KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jul-10-25 09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
07:00AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results (Business Wire)
Jul-09-25 08:16AM	KalVista price target raised to $37 from $22 at BofA (TipRanks) +6.96%
Jul-08-25 07:00AM	DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat) (PR Newswire)
Jul-07-25 06:09PM	KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment (Investor's Business Daily) +25.71%
11:34AM	Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat) (PR Newswire)
06:37AM	US FDA approves KalVista's oral swelling disorder drug, shares rise (Reuters)
06:30AM	KalVista Pharmaceuticals Announces FDA Approval of EKTERLY (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jul-02-25 04:05PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-25 06:03PM	Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada (PR Newswire)
07:00AM	KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada (Business Wire)
Jun-20-25 08:03AM	How KalVista Pharma Is Taking On A Rare But Deadly Disease (Investor's Business Daily)
Jun-18-25 09:31AM	FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use (Clinical Trials Arena)
Jun-16-25 07:00AM	KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis (Business Wire)
05:00AM	FDA to miss approval deadline for Kalvista drug due to resource constraints (BioPharma Dive)
Jun-13-25 04:05PM	KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints (Business Wire)
Jun-05-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 (Business Wire)
Jun-03-25 04:01PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-02-25 07:00AM	KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management (Business Wire) +9.49%
May-29-25 07:00AM	KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-22-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings (Business Wire)
May-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-30-25 07:00AM	KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference (Business Wire) +5.28%
Apr-12-25 12:42AM	KalVista: Poised For Rare Disease Transformation (Seeking Alpha)
Apr-08-25 10:27AM	KalVista licenses commercialisation rights for HAE to Kaken in Japan (Pharmaceutical Technology) -10.26%
06:30AM	KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan (Business Wire)
Apr-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-31-25 07:00AM	KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-25 11:14AM	KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial (Clinical Trials Arena)
Mar-25-25 07:00AM	KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial (Business Wire)
Mar-12-25 07:00AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire)
Mar-10-25 07:00AM	KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema (Business Wire)
Mar-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-25 07:00AM	KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-24-25 07:00AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-21-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire) -5.73%
Feb-10-25 07:00AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.75%
Jan-21-25 07:00AM	KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema (Business Wire) +5.42%
Jan-08-25 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.94%
Dec-16-24 07:00AM	KalVista Appoints Jeb Ledell as Chief Operating Officer (Business Wire)
Dec-05-24 06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-24 07:00AM	KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors (Business Wire)
Nov-12-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-05-24 07:29AM	KalVista Secures $184M Financing for Sebetralstat Launch (TipRanks)
06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-24 07:05AM	KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million (Business Wire) +9.61%
07:00AM	KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust (Business Wire)
Oct-28-24 06:30AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology (Business Wire)
Oct-18-24 06:30AM	KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) (Business Wire)
Oct-04-24 12:29PM	KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum (Business Wire)
Oct-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 06:30AM	KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -6.16%
Sep-26-24 06:30AM	KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) (Business Wire) +5.71%
Sep-10-24 07:00AM	KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (Business Wire) -5.56%
06:30AM	KalVista Appoints Brian Piekos as Chief Financial Officer (Business Wire)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Feb 12 '26	Sale	15.70	3,354	52,658	428,286	Feb 13 04:05 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Dec 08 '25	Sale	16.51	7,294	120,424	424,520	Dec 09 06:16 PM
Sweeny Nicole	Chief Commercial Officer	Nov 24 '25	Sale	13.45	3,813	51,289	39,728	Dec 04 04:02 PM
Piekos Brian	Chief Financial Officer	Nov 24 '25	Sale	13.45	4,471	60,139	10,529	Nov 26 06:50 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 24 '25	Sale	13.45	4,331	58,256	223,508	Nov 26 06:49 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 24 '25	Sale	13.45	5,296	71,236	131,831	Nov 26 06:47 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 24 '25	Sale	13.45	10,940	147,154	416,189	Nov 26 06:46 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 20 '25	Option Exercise	0.00	87,390	376	220,964	Nov 21 04:07 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Sale	14.48	4,466	64,665	403,879	Nov 19 04:13 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 18 '25	Sale	14.48	2,683	38,848	133,574	Nov 19 04:11 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 18 '25	Sale	14.48	3,075	44,524	125,877	Nov 19 04:11 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 12 '25	Sale	11.55	3,328	38,438	398,981	Nov 13 04:28 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Sep 08 '25	Sale	15.84	7,294	115,537	395,189	Sep 09 07:02 PM
Sweeny Nicole	Chief Commercial Officer	Aug 25 '25	Sale	13.42	1,480	19,862	32,291	Aug 26 08:00 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 25 '25	Sale	13.42	1,954	26,223	132,052	Aug 26 07:59 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 25 '25	Sale	13.42	2,336	31,349	122,505	Aug 26 07:57 PM
Sweeny Nicole	Chief Commercial Officer	Aug 22 '25	Sale	13.22	1,864	24,647	28,771	Aug 25 09:33 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 22 '25	Sale	13.22	2,362	31,232	130,881	Aug 25 07:46 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 22 '25	Sale	13.22	10,940	144,657	386,858	Aug 25 07:46 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 22 '25	Sale	13.22	2,942	38,901	119,841	Aug 25 07:45 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 18 '25	Sale	13.19	2,649	34,932	129,493	Aug 19 04:27 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 18 '25	Sale	13.19	2,939	38,757	116,533	Aug 19 04:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 18 '25	Sale	13.19	4,409	58,141	374,548	Aug 19 04:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jul 09 '25	Sale	15.69	32,979	517,523	369,595	Jul 10 08:56 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Jul 09 '25	Sale	15.69	30,250	474,698	127,939	Jul 10 08:50 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jun 09 '25	Sale	14.50	7,169	103,950	315,074	Jun 10 05:00 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 23 '25	Sale	11.31	2,146	24,272	113,026	May 27 04:06 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 23 '25	Sale	11.31	1,926	21,782	98,189	May 27 04:05 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 22 '25	Sale	11.88	2,689	31,933	110,172	May 23 04:26 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 22 '25	Sale	11.88	2,317	27,516	96,990	May 23 04:25 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 22 '25	Sale	11.88	9,999	118,743	306,618	May 23 04:24 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 19 '25	Sale	11.84	2,600	30,791	95,557	May 20 07:28 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 19 '25	Sale	11.84	3,808	45,097	293,367	May 20 07:28 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 19 '25	Sale	11.84	2,776	32,876	106,611	May 20 07:27 PM
Venrock Healthcare Capital Par	10% Owner	Apr 09 '25	Buy	9.42	25,000	235,500	5,303,985	Apr 11 05:22 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Mar 07 '25	Sale	11.97	6,669	79,828	287,811	Mar 10 06:43 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	10.02	2,394	23,988	102,940	Feb 25 08:37 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 24 '25	Sale	10.02	1,918	19,218	93,952	Feb 25 08:36 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 18 '25	Sale	9.82	2,601	25,553	92,745	Feb 19 08:47 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	9.82	3,125	30,701	100,334	Feb 19 08:46 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	9.82	5,104	50,143	278,855	Feb 19 08:46 PM

Open in Screener

ORKA

Oruka Therapeutics Inc

Feb 13 • 04:00PM ET

32.21

-0.43 -1.32 %

Healthcare • Biotechnology • USA • NASD

ORKA Oruka Therapeutics Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO IWC VFMO

Index	RUT	P/E	-	EPS (ttm)	-2.42	Insider Own	12.08%	Shs Outstand	48.38M	Perf Week	-2.54%
Market Cap	1.56B	Forward P/E	-	EPS next Y	-2.55	Insider Trans	-0.46%	Shs Float	42.56M	Perf Month	0.66%
Enterprise Value	1.21B	PEG	-	EPS next Q	-0.64	Inst Own	89.91%	Short Float	11.53%	Perf Quarter	13.82%
Income	-101.63M	P/S	-	EPS this Y	43.05%	Inst Trans	26.24%	Short Ratio	9.21	Perf Half Y	114.73%
Sales	0.00M	P/B	3.22	EPS next Y	-15.77%	ROA	-22.01%	Short Interest	4.91M	Perf YTD	6.27%
Book/sh	10.00	P/C	4.47	EPS next 5Y	9.89%	ROE	-23.05%	52W High	36.51 -11.78%	Perf Year	181.80%
Cash/sh	7.21	P/FCF	-	EPS past 3/5Y	33.13% 36.88%	ROIC	-20.81%	52W Low	5.49 487.24%	Perf 3Y	147.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.63% 6.00%	Perf 5Y	-3.65%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	63.85%	Oper. Margin	-	ATR (14)	2.00	Perf 10Y	-92.15%
Dividend Ex-Date	-	Quick Ratio	16.94	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.32	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	16.94	EPS Q/Q	63.96%	SMA20	-4.45%	Beta	-0.35	Target Price	58.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.24%	Rel Volume	0.35	Prev Close	32.64
Employees	28	LT Debt/Eq	0.00	Earnings	Nov 12 AMC	SMA200	54.71%	Avg Volume	532.74K	Price	32.21
IPO	Aug 08, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.68% -	Trades		Volume	187,043	Change	-1.32%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Piper Sandler	Overweight	$75
Nov-13-25	Initiated	Jefferies	Buy	$45
Oct-27-25	Initiated	Guggenheim	Buy	$60
Oct-13-25	Initiated	Barclays	Overweight	$48
May-22-25	Initiated	BTIG Research	Buy	$44
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Show Previous Ratings

Feb-09-26 07:00AM	Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
Jan-12-26 07:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 (GlobeNewswire) +10.16%
Jan-06-26 07:00AM	Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 04:01PM	Oruka Therapeutics Announces New Board Member and Board Transition (GlobeNewswire)
Nov-12-25 04:05PM	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.78%
09:55AM	Loading…
Oct-29-25 09:55AM	Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know (Zacks)
07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Sep-29-25 04:24PM	MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment (Investor's Business Daily) +26.91%
Sep-17-25 04:11PM	Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker (Investor's Business Daily) +8.79%
01:02AM	Oruka Therapeutics Announces $180 Million Private Placement (GlobeNewswire)
01:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 (GlobeNewswire)
Aug-11-25 04:04PM	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.90%
Jul-21-25 07:00AM	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September (GlobeNewswire) -5.30%
Jul-01-25 04:01PM	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire) +5.26% +6.86%
03:32PM	Loading…
May-27-25 03:32PM	H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial (Insider Monkey)
May-21-25 07:00AM	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire)
May-14-25 04:15PM	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
07:05AM	Loading…
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
May-11-21 04:15PM	ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-21 04:05PM	Christopher Graybill Joins ARCA as Vice President, Clinical Development (GlobeNewswire)
May-03-21 04:30PM	ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer (GlobeNewswire)
Mar-18-21 04:30PM	ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-13-21 01:09AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-15-20 08:30AM	ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 (GlobeNewswire)
Dec-09-20 05:40PM	ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders (GlobeNewswire)
Nov-23-20 12:28PM	ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment (MarketWatch) +7.46%
08:30AM	AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation (GlobeNewswire)
Nov-02-20 08:30AM	ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
Oct-07-20 08:30AM	ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -8.49%
Oct-05-20 04:30PM	ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality (GlobeNewswire) +12.61%
Sep-21-20 08:00AM	ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -10.62%

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Option Exercise	7.32	7,000	51,240	8,518	Jan 16 05:26 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Sale	31.81	7,000	222,704	1,518	Jan 16 05:26 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Option Exercise	7.80	5,000	39,000	218,084	Jan 02 08:25 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Sale	28.52	13,000	370,795	205,084	Jan 02 08:25 PM
LAURA SANDLER	Officer	Jan 02 '26	Proposed Sale	30.31	18,000	545,580		Jan 02 04:31 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Option Exercise	7.32	7,000	51,240	8,518	Dec 19 05:38 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Sale	30.61	7,000	214,293	1,518	Dec 19 05:38 PM
JOANA GONCALVES	Officer	Dec 19 '25	Proposed Sale	28.15	28,000	788,200		Dec 19 04:20 PM
Venrock Healthcare Capital Par	10% Owner	Feb 14 '25	Buy	11.44	88,794	1,015,803	4,148,428	Feb 27 06:42 PM

KALV

KalVista Pharmaceuticals Inc

ORKA

Oruka Therapeutics Inc

Upgrade your FINVIZ experience